Study Design and Rationale of a Dose‐Ranging Trial of LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy

Sodium‐glucose cotransporters 1 (SGLT1) and 2 (SGLT2) are the major cellular transporters responsible for gastrointestinal (GI) glucose absorption and renal glucose reabsorption, respectively. LX4211, a dual inhibitor of SGLT1 and SGLT2, reduces glucose absorption from the GI tract and enhances urin...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cardiol
Päätekijät: Lapuerta, Pablo, Rosenstock, Julio, Zambrowicz, Brian, Powell, David R., Ogbaa, Ike, Freiman, Joel, Cefalu, William T., Banks, Phillip, Frazier, Kenny, Kelly, Mike, Sands, Arthur
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Wiley Periodicals, Inc. 2013
Aiheet:
Trial Designs
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6649411/
https://ncbi.nlm.nih.gov/pubmed/23630033
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22125
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia